AXSOME THERAPEUTICS INC (AXSM)

Company Profile

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 383 full-time employees. The company went IPO on 2015-11-19. The firm is developing and delivering novel therapies for the central nervous system (CNS), conditions that have limited treatment options. The firm's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of the major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Its AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. Its AXS-07 is a multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Company Info

AXSOME THERAPEUTICS INC

One World Trade Center, 22Nd Floor

New York City NEW YORK 10038

P: 12123323241

CEO: Herriot Tabuteau

Employees: 383

Website: https://www.axsome.com/